<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>1812-9528</journal-id>
<journal-title><![CDATA[Memorias del Instituto de Investigaciones en Ciencias de la Salud]]></journal-title>
<abbrev-journal-title><![CDATA[Mem. Inst. Investig. Cienc. Salud]]></abbrev-journal-title>
<issn>1812-9528</issn>
<publisher>
<publisher-name><![CDATA[Instituto de Investigaciones en Ciencias de la Salud]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S1812-95282018000300013</article-id>
<article-id pub-id-type="doi">10.18004/mem.iics/1812-9528/2018.016(03)13-021</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Estudio comparativo de perfiles de disolución de tabletas de prednisona 20 mg comercializados en Perú]]></article-title>
<article-title xml:lang="en"><![CDATA[Comparative study of dissolution profiles of prednisone 20 mg tablets marketed in Peru]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Casanova-Godoy]]></surname>
<given-names><![CDATA[Luis Antonio Martín]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Castillo-Saavedra]]></surname>
<given-names><![CDATA[Ericson Félix]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Reynoso-Leyva]]></surname>
<given-names><![CDATA[Elva Milagros]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Ayala-Jara]]></surname>
<given-names><![CDATA[Carmen Isolina]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Universidad Nacional de Trujillo Facultad de Farmacia y Bioquímica ]]></institution>
<addr-line><![CDATA[Trujillo ]]></addr-line>
<country>Peru</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>12</month>
<year>2018</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>12</month>
<year>2018</year>
</pub-date>
<volume>16</volume>
<numero>3</numero>
<fpage>13</fpage>
<lpage>21</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://scielo.iics.una.py/scielo.php?script=sci_arttext&amp;pid=S1812-95282018000300013&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.iics.una.py/scielo.php?script=sci_abstract&amp;pid=S1812-95282018000300013&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.iics.una.py/scielo.php?script=sci_pdf&amp;pid=S1812-95282018000300013&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[RESUMEN El estudio tuvo como finalidad comparar los perfiles de disolución de tabletas de prednisona 20 mg comercializados en Perú. Se realizó un estudio cuantitativo comparativo con diseño no experimental, que incluyó doce tabletas para cada formulación a evaluar (referente y multifuente), bajo condiciones similares de trabajo, en tres medios de disolución: buffer ácido clorhídrico pH 1,2; buffer acetato pH 4,5 y buffer fosfato pH 6,8. Los porcentajes temporales disueltos de prednisona fueron evaluados mediante el orden cinético cero, uno, Higuchi, raíz cúbica y Weibull para el modelo dependiente; mientras que el factor de similitud (f2), tiempo medio de disolución y eficiencia de disolución fueron utilizados para el modelo independiente. En el modelo dependiente, la liberación de prednisona; se ajustó a la cinética de función de Weibull; evaluada mediante el criterio de información de Akaike. En el modelo independiente, los valores de f2 en todos los medios de disolución cumplieron con el rango 50 - 100 establecida por la Food and Drug Adminstration, para indicar similitud in vitro entre los perfiles de disolución. Asimismo, se evidenció que no existe diferencia estadísticamente significativa entre las formulaciones, respecto al tiempo medio de disolución y la eficiencia de disolución. Las tabletas de prednisona 20 mg referente y multifuente comercializados en Perú son similares, con base en pruebas de perfiles de disolución in vitro.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[ABSTRACT The purpose of the study was to compare the dissolution profiles of prednisone 20 mg tablets marketed in Peru. A comparative quantitative study with a non-experimental design was carried out, which included twelve tablets for each formulation to be evaluated (referent and multi-source), under similar work conditions in three dissolution media: hydrochloric acid buffer pH 1.2, acetate buffer pH 4.5 and phosphate buffer pH 6.8. The dissolved temporal percentages of prednisone were evaluated by zero kinetic order and first kinetic order, Higuchi, cubic root and Weibull models for the dependent model; while the similarity factor (f2), mean dissolution time and dissolution efficiency were used for the independent model. In the dependent model, the release of prednisone was adjusted to the Weibull function kinetics, evaluated using the Akaike information criterion. In the independent model, the values of f2 in all the dissolution media fulfilled the range 50 - 100 established by the Food and Drug Administration, to indicate in vitro similarity between the dissolution profiles. Likewise, it was evidenced that there is no statistically significant difference between the formulations with respect to the mean dissolution time and the dissolution efficiency. The reference and multi-source prednisone 20 mg tablets marketed in Peru are similar based on in vitro dissolution profiles tests.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[disolución]]></kwd>
<kwd lng="es"><![CDATA[prednisona]]></kwd>
<kwd lng="es"><![CDATA[liberación de fármaco]]></kwd>
<kwd lng="es"><![CDATA[técnicas in vitro (Fuente: DeCS BIREME)]]></kwd>
<kwd lng="en"><![CDATA[dissolution]]></kwd>
<kwd lng="en"><![CDATA[prednisone]]></kwd>
<kwd lng="en"><![CDATA[drug release]]></kwd>
<kwd lng="en"><![CDATA[in vitro techniques (Source: MeSH NLM)]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Huayanay]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Bioequivalencia en medicamentos]]></article-title>
<source><![CDATA[Rev Med Hered]]></source>
<year>2012</year>
<volume>23</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>221-2</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Estévez]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Parrillo]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Cedrés]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Estudios de bioequivalencia in vivo para demostrar la intercambiabilidad de medicamentos]]></article-title>
<source><![CDATA[Rev. Méd. Urug]]></source>
<year>2012</year>
<volume>28</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>165-73</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Swami]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Singh]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Bhasin]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Dureja]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[In vitro dissolution profile comparison: a tool for biowaivers based on BCS]]></article-title>
<source><![CDATA[J Pharm Res]]></source>
<year>2011</year>
<volume>10</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>73-6</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gao]]></surname>
<given-names><![CDATA[Z]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[In Vitro dissolution testing with flow-through method: A technical note]]></article-title>
<source><![CDATA[AAPS PharmSciTech]]></source>
<year>2009</year>
<volume>10</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>1401-5</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Saranadasa]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Krishnamoorthy]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A multivariate test for similarity of two dissolution profiles]]></article-title>
<source><![CDATA[J Biopharm Stat]]></source>
<year>2005</year>
<volume>15</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>265-78</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gomez]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Schaefer]]></surname>
<given-names><![CDATA[U]]></given-names>
</name>
<name>
<surname><![CDATA[Casabo]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Lehr]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Lehr]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Statistical comparison of dissolution profiles to predict the bioequivalence of extended release formulations]]></article-title>
<source><![CDATA[The AAPS Journal]]></source>
<year>2014</year>
<volume>16</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>791-801</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="">
<collab>Food and drug administration (FDA)</collab>
<source><![CDATA[Guía para la Industria: Pruebas de disolución de formas de dosificación oral sólidas de liberación inmediata]]></source>
<year>2010</year>
</nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pérez]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Orobio]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Baena]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Estudio comparativo de la liberación in vitro de metformina, a partir de dos productos multifuente de liberación inmediata, comercializados en Colombia]]></article-title>
<source><![CDATA[Rev. Colomb. Cienc. Quím. Farm.]]></source>
<year>2013</year>
<volume>42</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>169-89</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Medina]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Hurtado]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Cortés]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Domínguez]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Disolución comparativa de indometacina en cápsulas utilizando los Aparatos 1 y 4 USP]]></article-title>
<source><![CDATA[Rev. mex. cienc. Farm]]></source>
<year>2012</year>
<volume>43</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>72-80</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="confpro">
<collab>World Health Organization</collab>
<source><![CDATA[Proposal to waive in vivo bioequivalence requirements for WHO Model list of Essential Medicines immediate-release, solid oral dosage forms]]></source>
<year>2006</year>
<conf-name><![CDATA[ 40Annex 8 of WHO Expert committee on specifications for pharmaceutical preparations]]></conf-name>
<conf-loc> </conf-loc>
<publisher-loc><![CDATA[Génova ]]></publisher-loc>
</nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Henrique]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Deris]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Antunes]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Prednisone raw material characterization and formulation development]]></article-title>
<source><![CDATA[Braz. J. Pharm. Sci.]]></source>
<year>2017</year>
<volume>53</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>1-14</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="book">
<source><![CDATA[Farmacopea de los Estados Unidos de América - USP 41 - NF 35]]></source>
<year>2017</year>
<volume>3</volume>
<page-range>5989-90</page-range><publisher-loc><![CDATA[Rockville ]]></publisher-loc>
<publisher-name><![CDATA[The United States Pharmacopeial Convention]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Navarro]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Cabral]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Aplicación de métodos modelo-dependiente y modelo-independiente en el desarrollo de una formulación de comprimidos de captopril]]></article-title>
<source><![CDATA[Rev. Colomb. Cienc. Quím. Farm.]]></source>
<year>2009</year>
<volume>38</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>19-30</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Moellenhoff]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Dette]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Kotzagiorgis]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Volgushev]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Collignon]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Regulatory assessment of drug dissolution profiles comparability via maximum deviation]]></article-title>
<source><![CDATA[Stat Med]]></source>
<year>2018</year>
<volume>37</volume>
<numero>20</numero>
<issue>20</issue>
<page-range>2968-81</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Simionato]]></surname>
<given-names><![CDATA[LD]]></given-names>
</name>
<name>
<surname><![CDATA[Petrone]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Baldut]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Bonafede]]></surname>
<given-names><![CDATA[SL]]></given-names>
</name>
<name>
<surname><![CDATA[Segall]]></surname>
<given-names><![CDATA[AI]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Comparison between the dissolution profiles of nine meloxicam tablet brands commercially available in Buenos Aires, Argentina]]></article-title>
<source><![CDATA[Saudi Pharm J]]></source>
<year>2018</year>
<volume>26</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>578-84</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
